Shots:
- Henlius has granted Sandoz exclusive rights of the HLX13, a biosimilar version of Yervoy (ipilimumab), which is being assessed in a Henlius-led P-I/III trial for inoperable HCC, targeting enrollment of 656 pts
- As per the deal, Sandoz will register & market HLX13 in Australia, Canada, EU, Japan, & the US in exchange for milestone-based payment of ~$301M, incl. $31M upfront post Yervoy patent expiry by Feb 2026 in the EU & Mar 2025 in the US, while Henlius will handle development & manufacturing
- Also, Sandoz is assessing its Opdivo biosimilar in P-I/III trial for advanced melanoma with a target enrollment of 720 pts & expects to launch its denosumab biosimilars, Wyost & Jubbonti, in the US by Q2’25 & EU by Q4’25
Ref: Sandoz | Image: Sandoz & Henlius
Related News:- Shanghai Henlius Biotech and Organon Reports EMA’s Validation of HLX11 (Biosimilar, Perjeta)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
